Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study

Authors: Yi-Chun Chen, Tzu-Yao Chang, Jien-Wei Liu, Fang-Ju Chen, Chun-Chih Chien, Chen-Hsiang Lee, Cheng-Hsien Lu

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

This study aimed to investigate the rate of fluconazole-non-susceptible Cryptococcus neoformans in Southern Taiwan for the period 2001–2012 and analyze the risk factors for acquiring it among patients with invasive cryptococcosis.

Methods

All enrolled strains were isolated from blood or cerebrospinal fluid samples of the included patients. If a patient had multiple positive results for C. neoformans, only the first instance was enrolled. Susceptibility testing was performed using the Clinical and Laboratory Standards Institutes M27-A3 broth micro-dilution method. The MIC interpretative criteria for susceptibility to fluconazole were ≤8 μg/ml. A total of 89 patients were included. Patients (n = 59) infected by fluconazole-susceptible strains were compared with those (n = 30) infected by non-susceptible strains. The patients’ demographic and clinical characteristics were analyzed.

Results

The rate of fluconazole-non-susceptible C. neoformans in the study period significantly increased over time (p < 0.001). The C. neoformans isolated in 2011–2012 (odds ratio: 10.68; 95 % confidence interval: 2.87-39.74; p < 0.001) was an independent predictive factor for the acquisition of fluconazole-non-susceptible C. neoformans.

Conclusions

The rate of fluconazole-non-susceptible C. neoformans has significantly increased recently. Continuous and large-scale anti-fungal susceptibility tests for C. neoformans are warranted to confirm this trend.
Literature
1.
go back to reference Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515–48.PubMedPubMedCentral Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515–48.PubMedPubMedCentral
2.
go back to reference Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.CrossRefPubMed Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.CrossRefPubMed
3.
go back to reference Patel S, Shin GY, Wijewardana I, Vitharana SR, Cormack I, Pakianathan M, et al. The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. J Infection. 2013;66:75–9.CrossRef Patel S, Shin GY, Wijewardana I, Vitharana SR, Cormack I, Pakianathan M, et al. The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. J Infection. 2013;66:75–9.CrossRef
4.
go back to reference Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis. 1998;26:186–7.CrossRefPubMed Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis. 1998;26:186–7.CrossRefPubMed
5.
go back to reference Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resist Updat. 1999;2:259–69.CrossRefPubMed Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resist Updat. 1999;2:259–69.CrossRefPubMed
6.
go back to reference Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol. 2012;50:3952–9.CrossRefPubMedPubMedCentral Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol. 2012;50:3952–9.CrossRefPubMedPubMedCentral
7.
go back to reference Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, et al. Anti-fungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multi-center antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother. 2005;49:512–7.CrossRefPubMedPubMedCentral Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, et al. Anti-fungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multi-center antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother. 2005;49:512–7.CrossRefPubMedPubMedCentral
8.
go back to reference Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR, Group for Enteric R, et al. Trends in anti-fungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002–2003 and 2007–2008. Antimicrob Agents Chemother. 2011;55:2606–11.CrossRefPubMedPubMedCentral Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR, Group for Enteric R, et al. Trends in anti-fungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002–2003 and 2007–2008. Antimicrob Agents Chemother. 2011;55:2606–11.CrossRefPubMedPubMedCentral
9.
go back to reference Gullo FP, Rossi SA, Sardi Jde C, Teodoro VL, Mendes-Giannini MJ, Fusco-Almeida AM. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis. 2013;32:1377–91.CrossRefPubMed Gullo FP, Rossi SA, Sardi Jde C, Teodoro VL, Mendes-Giannini MJ, Fusco-Almeida AM. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis. 2013;32:1377–91.CrossRefPubMed
10.
go back to reference Lee CH, Chang TY, Liu JW, Chen FJ, Chien CC, Tang YF, et al. Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis. BMC Infect Dis. 2012;12:361.CrossRefPubMedPubMedCentral Lee CH, Chang TY, Liu JW, Chen FJ, Chien CC, Tang YF, et al. Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis. BMC Infect Dis. 2012;12:361.CrossRefPubMedPubMedCentral
11.
go back to reference Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis. 2006;43:1069–73.CrossRefPubMed Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis. 2006;43:1069–73.CrossRefPubMed
12.
go back to reference Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother. 2004;54:563–5.CrossRefPubMed Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother. 2004;54:563–5.CrossRefPubMed
13.
go back to reference Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, et al. In vitro anti-fungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol. 2011;60:961–7.CrossRefPubMed Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, et al. In vitro anti-fungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol. 2011;60:961–7.CrossRefPubMed
14.
go back to reference Eisenman HC, Casadevall A, McClelland EE. New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Rep. 2007;9:457–64.CrossRefPubMed Eisenman HC, Casadevall A, McClelland EE. New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Rep. 2007;9:457–64.CrossRefPubMed
15.
go back to reference Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.CrossRefPubMed Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.CrossRefPubMed
16.
go back to reference American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74
17.
go back to reference Fenn JP, Segal H, Barland B, Denton D, Whisenant J, Chun H, et al. Comparison of updated Vitek Yeast Biochemical Card and API 20C yeast identification systems. J Clin Microbiol. 1994;32:1184–7.PubMedPubMedCentral Fenn JP, Segal H, Barland B, Denton D, Whisenant J, Chun H, et al. Comparison of updated Vitek Yeast Biochemical Card and API 20C yeast identification systems. J Clin Microbiol. 1994;32:1184–7.PubMedPubMedCentral
18.
go back to reference Ito-Kuwa S, Nakamura K, Aoki S, Vidotto V. Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses. 2007;50:277–81.CrossRefPubMed Ito-Kuwa S, Nakamura K, Aoki S, Vidotto V. Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses. 2007;50:277–81.CrossRefPubMed
19.
go back to reference Aoki FH, Imai T, Tanaka R, Mikami Y, Taguchi H, Nishimura NF, et al. New PCR primer pairs specific for Cryptococcus neoformans serotype A or B prepared on the basis of random amplified polymorphic DNA fingerprint pattern analyses. J Clin Microbiol. 1999;37:315–20.PubMedPubMedCentral Aoki FH, Imai T, Tanaka R, Mikami Y, Taguchi H, Nishimura NF, et al. New PCR primer pairs specific for Cryptococcus neoformans serotype A or B prepared on the basis of random amplified polymorphic DNA fingerprint pattern analyses. J Clin Microbiol. 1999;37:315–20.PubMedPubMedCentral
20.
go back to reference Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution anti-fungal susceptibility testing of yeasts; approved standard. 3rd ed. Wayne, PA: CLSI document M27–A3, CLSI; 2008. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution anti-fungal susceptibility testing of yeasts; approved standard. 3rd ed. Wayne, PA: CLSI document M27–A3, CLSI; 2008.
21.
go back to reference Dannaoui E, Abdul M, Arpin M, Michel-Nguyen A, Piens MA, Favel A, et al. Results obtained with various anti-fungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother. 2006;50:2464–70.CrossRefPubMedPubMedCentral Dannaoui E, Abdul M, Arpin M, Michel-Nguyen A, Piens MA, Favel A, et al. Results obtained with various anti-fungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother. 2006;50:2464–70.CrossRefPubMedPubMedCentral
22.
go back to reference Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, et al. Results from the ARTEMIS DISK Global Anti-fungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of non-candidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2009;47:117–23.CrossRefPubMed Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, et al. Results from the ARTEMIS DISK Global Anti-fungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of non-candidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2009;47:117–23.CrossRefPubMed
23.
go back to reference Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. Cryptococcus neoformans strains and infection in apparently immuno-competent patients, China. Emerg Infect Dis. 2008;14:755–62.CrossRefPubMedPubMedCentral Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. Cryptococcus neoformans strains and infection in apparently immuno-competent patients, China. Emerg Infect Dis. 2008;14:755–62.CrossRefPubMedPubMedCentral
24.
go back to reference Choi YH, Ngamskulrungroj P, Varma A, Sionov E, Hwang SM, Carriconde F, et al. Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res. 2010;10:769–78.CrossRefPubMedPubMedCentral Choi YH, Ngamskulrungroj P, Varma A, Sionov E, Hwang SM, Carriconde F, et al. Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res. 2010;10:769–78.CrossRefPubMedPubMedCentral
25.
go back to reference Pan W, Khayhan K, Hagen F, Wahyuningsih R, Chakrabarti A, Chowdhary A, et al. Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes. PLoS One. 2012;7:e32868.CrossRefPubMedPubMedCentral Pan W, Khayhan K, Hagen F, Wahyuningsih R, Chakrabarti A, Chowdhary A, et al. Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes. PLoS One. 2012;7:e32868.CrossRefPubMedPubMedCentral
26.
go back to reference Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012;56:5898–906.CrossRefPubMedPubMedCentral Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012;56:5898–906.CrossRefPubMedPubMedCentral
27.
go back to reference Tseng HK, Liu CP, Ho MW, Lu PL, Lo HJ, Lin YH, et al. Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997–2010. PLoS One. 2013;8:e61921.CrossRefPubMedPubMedCentral Tseng HK, Liu CP, Ho MW, Lu PL, Lo HJ, Lin YH, et al. Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997–2010. PLoS One. 2013;8:e61921.CrossRefPubMedPubMedCentral
28.
go back to reference Guinea J, Hagen F, Pelaez T, Boekhout T, Tahoune H, Torres-Narbona M, et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol. 2010;48:942–8.CrossRefPubMed Guinea J, Hagen F, Pelaez T, Boekhout T, Tahoune H, Torres-Narbona M, et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol. 2010;48:942–8.CrossRefPubMed
29.
go back to reference Cheong JW, McCormack J. Fluconazole resistance in cryptococcal disease: emerging or intrinsic? Med Mycol. 2013;51:261–9.CrossRefPubMed Cheong JW, McCormack J. Fluconazole resistance in cryptococcal disease: emerging or intrinsic? Med Mycol. 2013;51:261–9.CrossRefPubMed
30.
go back to reference Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. 2011;75:213–67.CrossRefPubMedPubMedCentral Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. 2011;75:213–67.CrossRefPubMedPubMedCentral
31.
go back to reference Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, et al. Hetero-resistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother. 1999;43:1856–61.PubMedPubMedCentral Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, et al. Hetero-resistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother. 1999;43:1856–61.PubMedPubMedCentral
32.
go back to reference Sionov E, Lee H, Chang YC, Kwon-Chung KJ. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010;6:e1000848.CrossRefPubMedPubMedCentral Sionov E, Lee H, Chang YC, Kwon-Chung KJ. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010;6:e1000848.CrossRefPubMedPubMedCentral
Metadata
Title
Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study
Authors
Yi-Chun Chen
Tzu-Yao Chang
Jien-Wei Liu
Fang-Ju Chen
Chun-Chih Chien
Chen-Hsiang Lee
Cheng-Hsien Lu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-1023-8

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue